Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

Compare with peers Embed
The 10-K against last year's

151 changes: 17 added, 17 removed, 111 reworded, 6 quiet changes

10-K Feb 26, 2026 vs Feb 28, 2025

10-K 0001384101-26-000010 (Feb 26, 2026) vs 10-K 0001384101-25-000014 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

369 paragraphs · 11 new · 119 reworded · 10 gone · 10-K Feb 26, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 116 · 50% changed Every version of it
In May 2024, the FDA published a final rule to phase out its policy of enforcement discretion over LDTs, and that rule was vacated by a federal district court on March 31, 2025. As part of the phaseout policy, the FDA intends to continue to exercise its current enforcement discretion in certain areas. For example, the FDA intends generally not to enforce Quality System Requirements (except for requirements under Part 820, subpart M, § 820.186 Quality system record) and Premarket Review for currently marketed IVDs offered as LDTs that were first marketed prior to May 6, 2024 and have not been significantly modified thereafter. Additionally, the FDA intends to exercise enforcement discretion and generally not enforce Premarket Review requirements for LDTs approved by the New York State Clinical Lab Evaluation Program, or NYS CLEP. However, while the enforcement policy is phased out, policy, the FDA could still decide to pursue enforcement action at any time against LDTs that it deems to be violative of its regulations when appropriate.
Paragraph 85 · 48% changed Every version of it
For example, we rely on NanoString (now Bruker Corporation Spatial Biology as a result of Bruker Corporation’s asset acquisition of NanoString) for certain components and raw materials for the Lymphmark and Prosigna test and nCounter service kits, as well as service of the nCounter Analysis System. In February 2024, NanoString filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court in Delaware and in May 2024, Bruker Corporation closed its asset acquisition of the business of NanoString. We are actively participating in the NanoString bankruptcy proceedings and may experience disruption in the supply or services as a result of the NanoString bankruptcy proceedings or the acquisition of certain assets by Bruker Corporation. As a result, we have and may continue to experience quality, regulatory, or manufacturing irregularities and challenges. kits.
Paragraph 256 · 47% changed Every version of it
Additionally, while the CJEU generally confirmed the validity of the European Commission-approved SCCs as a personal data-protective transfer mechanism, it made clear that reliance on the SCCs alone may not necessarily be sufficient in all circumstances. Use of the SCCs must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. In response to the CJEU decision, the European Commission has published revised SCCs, which we implemented in advance of the December 27, 2022 deadline. The revised SCCs are not to be relied on for data transfers to non-EEA entities subject to the GDPR, and we are waiting for further guidance on valid mechanisms for data transfers from the EEA to such entities. As a result, we may have to make certain operational changes, and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames.
Paragraph 272 · 47% changed Every version of it
The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology and diagnostics, which may make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions may result in substantial cost and divert our efforts and attention from other aspects of our business.
Paragraph 48 · 47% changed Every version of it
For example, if we are unable to provide payers with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, may provide limited coverage or may terminate coverage, which will adversely affect our revenues and our financial condition. Since each payer makes its own decision as to whether to establish a coverage policy or enter into a contract to reimburse our tests, seeking these approvals is a time-consuming and costly process. Other countries, as well as some private payers, also control the price of health care products, directly or indirectly, through reimbursement, payment, pricing or coverage limitations, tying reimbursement to outcomes or (in the case of governmental entities) through compulsory licensing or limiting of intellectual property protections.
Paragraph 72 · 44% changed Every version of it
•We may have difficulties integrating C2i’s whole-genome, AI-powered technology into our tests, and we may identify flawed algorithms or insufficient or biased datasets, which could adversely impact the reliability of our data and subject us to delays and competitive harm, regulatory action, or legal liability, as well as brand or reputational harm;
Paragraph 185 · 42% changed Every version of it
We continually seek to develop enhancements to our test offerings and additional diagnostic tests that requires us to devote considerable resources to research and development. We may face challenges obtaining sufficient numbers of samples to validate a genomic signature for our products. We must provide sufficient clinical and analytical validity, as well as clinical utility studies that meet individual payer evidence requirements to obtain reimbursement. Even after launching new products, we must complete additional studies that meet the clinical evidence required by individual payers to obtain reimbursement.
Paragraph 368 · 42% changed Every version of it
There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance, or ESG, matters. Some investors may use these non-financial performance factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and actions relating to corporate responsibility are inadequate. In addition, corporate responsibility criteria with respect to ESG could change, which could result in greater expectations of us and cause us to undertake more costly initiatives to satisfy such new criteria. For example, in 2023, California passed new climate bills governing disclosure of climate house gas emissions data, climate-related financial risks, and details around emissions-related claims and carbon offsets. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate and we may be subject to fines from regulatory authorities and may harm our reputation. We may face reputational damage in the event that we do not meet the ESG standards set by various constituencies. In addition, the SEC recently adopted a rule that requires climate disclosures in periodic and other filings with the SEC, which rule has been stayed pending the completion of a judicial review. To comply with this SEC rule, if such rule goes into effect in its current form, we will be required to establish additional internal controls, engage additional consultants and incur additional costs related to evaluating, managing and reporting on our environmental impact and climate-related risks and opportunities. If we fail to implement sufficient oversight or accurately capture and disclose on environmental matters, our reputation, business, operating results and financial condition may be materially adversely affected.

MD&A

103 paragraphs · 6 new · 57 reworded · 7 gone · 10-K Feb 26, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 70 · 47% changed
Research and development expense increased $12.0 $1.5 million, or 21%, 2%, for the year ended December 31, 2024 2025 compared to 2023. 2024. The increase was is primarily driven by due to annual compensation expense due to increased headcount and acquired expenses related to the C2i Acquisition, our allocated costs from general and administrative expenses. Spend supporting direct research and product development expense related to our on-going ongoing development costs for our IVD CLIA tests and MRD strategies, as well as projects to enhance the efficiency of our laboratories. In addition to these development costs, the increase is partially driven by clinical studies including, strategies increased but not limited to, furthering the support and clinical utility evidence of our Percepta Nasal Swab test, as well as our urology products. These investments were partially was offset by the reduction impact of the deconsolidation of Veracyte SAS in tech access fees recognized in 2023 under other expenses. August 2025.
Paragraph 76 · 47% changed
General and administrative expense increased $24.4 $0.2 million, or 28%, for the year ended December 31, 2024 2025 compared to 2023. 2024. Professional fees increased $11.9 million primarily due to fees related to the Veracyte SAS collective proceedings petition filing and other consulting spend. Compensation expense increased primarily due to expenses related to restructuring costs associated with annual merit increases, additional headcount and higher stock-based compensation, partially offset by the voluntary termination plan at our Marseille location, annual compensation increases and expenses prior year expense related to the C2i Acquisition. voluntary exits of Veracyte SAS employees in connection with the deconsolidation of Veracyte SAS in August 2025. Information technology and occupancy expenses increased primarily due to additional cloud infrastructure supporting our C2i Acquisition, expansion of MRD platform, TrueMRD, and infrastructure development for our facilities footprint to support testing growth and our Marseille site, and additional infrastructure build out. order-to-cash operations. Contingent consideration increased $7.6 decreased $17.5 million primarily due to a $5.4 million reversal the revaluation of contingent consideration expense recorded in 2023 related to our the acquisitions of C2i and nCounter Analysis System acquisition. diagnostic rights. General and administrative expenses related to occupancy costs and information technology costs are allocated to general and administrative expense, selling and marketing expense, research and development expense, and cost of revenue based on the headcount and employee location.
Paragraph 61 · 40% changed
Biopharmaceutical and other revenue decreased by $5.8 $3.5 million for the year ended December 31, 2024 2025 compared to 2023 driven primarily by 2024, due to the reduction of customer projects decrease in the business conducted in France given overall spending constraints across the industry. restructuring proceedings affecting Veracyte SAS in August 2025.
Paragraph 43 · 40% changed
Other income (loss), net consists primarily of interest income from our cash held in interest bearing accounts, realized and unrealized gains and losses on foreign currency transactions, and and, prior to the restructuring proceedings affecting Veracyte SAS in August 2025, French research tax credits. The French research tax credits (crédit d’impôt recherche, or CIR) are generated by our wholly owned subsidiary, credits, as well as loss on deconsolidation of Veracyte SAS, in connection with its research efforts performed in Marseille, France. SAS.
Paragraph 50 · 38% changed
We recognize stock-based compensation expense for only those shares underlying stock options and restricted stock units that we expect to vest on a straight-line basis over the requisite service period of the award. We estimate the fair value of stock options using a Black-Scholes option-pricing model, which requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Performance-based stock units, which vest upon the achievement of certain performance conditions, are subject to the employees’ continued service with us. The probability of vesting is assessed at each reporting period and compensation cost is adjusted based on this probability assessment. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.
Paragraph 37 · 38% changed
Our cost of biopharmaceutical and other revenue are the consists of costs of performing activities under arrangements that require us to perform license or provide access to our assets or laboratory testing services, as well as costs incurred in providing contracted research and development, contract testing services, commercialization, development and contract manufacturing and development. This expense is activities. These costs are mainly composed of compensation, manufacturing and laboratory supplies, and pass-through costs. Following the restructuring proceedings affecting Veracyte SAS in August 2025, the Company no longer performs contract research, development and manufacturing services.
Paragraph 60 · 37% changed
Revenue Product revenue increased $84.7 $0.7 million, or 23%, 5%, for the year ended December 31, 2024 2025 compared to 2023. This was 2024, driven primarily due to a $92.4 million increase in testing revenue driven by a 23% volume increase and a 4% improved average selling price increase, partially offset by a $5.8 million decrease in our Biopharmaceutical and other revenue, as well as a $1.9 million decrease in our product revenue. per test.
Paragraph 67 · 36% changed
Cost of biopharmaceutical and other revenue includes labor costs, laboratory supplies and pass-through expenses incurred. Cost of biopharmaceutical and other revenue decreased by $2.9 $4.8 million driven by reductions the decrease in biopharmaceutical services, as well as contract development and manufacturing services projects, prior to the ultimate deconsolidation of staffing and variable expenses related to projects. Veracyte SAS in August 2025.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors262 words changed in this paragraph; it is 55% similar to last year's version.
We are subject to income taxes in the United States and various foreign jurisdictions. Our effective tax rate may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our revenue from country to country, the establishment or release of valuation allowances against our deferred tax assets, and changes in tax laws. In addition, we have recorded gross unrecognized tax benefits in our consolidated financial statements that, if recognized, would impact our effective tax rate. We are subject to tax audits in various jurisdictions, including the United States, and tax authorities may disagree with certain positions we have taken and assess additional taxes. There can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes could have a material impact on our net income or financial condition. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business and results of operations. We recognize deferred tax assets when the tax benefit is considered to be more likely than not of being realized; otherwise, a valuation allowance is applied against deferred tax assets. Assessing the recoverability of deferred tax assets requires management to make significant estimates based on historical income, projected future income, the expected timing of the reversals of existing temporary differences, the implementation of tax-planning strategies and the application of specific tax laws in each jurisdiction. Changes in these estimates or assumptions, including changes in future profitability or taxable income, could result in the establishment, increase, or reversal of valuation allowances. Given our current earnings, we believe that, within the next 12 months, sufficient positive evidence may become available to allow us to reach a conclusion that a portion of the valuation allowance recorded against the deferred tax assets held may be reversed. A reversal would result in an income tax benefit for the quarterly and annual period in which we determine to release the valuation allowance. The impact of releasing some or all of such valuation allowance in a future period could be material in the period in which such release occurs. However, the exact timing and amount of a valuation allowance release are subject to change on the basis of the level of profitability that we actually achieve. To the extent that future cash flows and taxable income differ significantly from estimates, our ability to realize the deferred tax assets could be impacted.

Source: Item 1A, 10-K 0001384101-26-000010 vs Item 1A, 10-K 0001384101-25-000014

MD&A153 words changed in this paragraph; it is 47% similar to last year's version.
General and administrative expense increased $24.4 $0.2 million, or 28%, for the year ended December 31, 2024 2025 compared to 2023. 2024. Professional fees increased $11.9 million primarily due to fees related to the Veracyte SAS collective proceedings petition filing and other consulting spend. Compensation expense increased primarily due to expenses related to restructuring costs associated with annual merit increases, additional headcount and higher stock-based compensation, partially offset by the voluntary termination plan at our Marseille location, annual compensation increases and expenses prior year expense related to the C2i Acquisition. voluntary exits of Veracyte SAS employees in connection with the deconsolidation of Veracyte SAS in August 2025. Information technology and occupancy expenses increased primarily due to additional cloud infrastructure supporting our C2i Acquisition, expansion of MRD platform, TrueMRD, and infrastructure development for our facilities footprint to support testing growth and our Marseille site, and additional infrastructure build out. order-to-cash operations. Contingent consideration increased $7.6 decreased $17.5 million primarily due to a $5.4 million reversal the revaluation of contingent consideration expense recorded in 2023 related to our the acquisitions of C2i and nCounter Analysis System acquisition. diagnostic rights. General and administrative expenses related to occupancy costs and information technology costs are allocated to general and administrative expense, selling and marketing expense, research and development expense, and cost of revenue based on the headcount and employee location.

Source: Item 7, 10-K 0001384101-26-000010 vs Item 7, 10-K 0001384101-25-000014

Accounting Policies71 words changed in this paragraph; it is 51% similar to last year's version.
Cost of product revenue consists primarily of costs of purchasing diagnostic kit components, components and reagents, labor, installation, service delivery costs and packaging and delivery costs. In addition, cost of product includes royalty costs royalties for licensed technologies included in the Company’s products. Subsequent to the restructuring proceedings affecting Veracyte SAS in August 2025, the costs of diagnostic kit components and reagents and labor costs are paid to a third-party contract manufacturer. The cost of the finished product is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the consolidated statements of operations.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001384101-26-000010 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001384101-25-000014

Legal Proceedings51 words changed in this paragraph; it is 80% similar to last year's version.
The Company leases office and laboratory facilities in the United States, including in South San Francisco and San Diego, California; California and Austin, Texas; Marseille, France; Richmond, Virginia; and Watertown, Massachusetts, Texas, and leases certain equipment under various non-cancelable lease agreements. Effective August 2025, in connection with the restructuring proceeding in Veracyte SAS, the Company is no longer a party to its lease in Marseille, France. The lease terms of the Company’s leases as of December 31, 2025 extend to March 2040 and contain extension of lease term and expansion options. The leases have a weighted average remaining lease term of 11.7 11.2 years as of December 31, 2024. 2025. The Company had deposits of $1.5 $1.6 million and $0.9 $1.5 million included in long-term assets as of December 31, 2024 2025 and 2023, 2024, respectively, restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the leases.

Source: Item 3, via Note 7 – Commitments and Contingencies, 10-K 0001384101-26-000010 vs Item 3, via Note 7 – Commitments and Contingencies, 10-K 0001384101-25-000014

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of VCYT's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•Prior to its acquisition, C2i was not required to maintain internal controls that would meet the requirements of a public company. Given the limited size and scope of C2i’s operations, its inclusion in the Company’s consolidated financial statements does not have a material impact on the Company’s internal control over financial reporting. The Company has integrated C2i into its existing internal control framework where appropriate and will continue to evaluate control needs as integration activities progress;
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
specifications, could negatively impact our ability to provide timely response and reports to our customers and, as a result, may materially impact our ability to generate revenue.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
to Class I or II for a new product type, and clinical data may be required. For laboratory tests for which FDA clearance, authorization or approval is required, the FDA may also require data to support analytical and clinical validity.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 56
AddedRisk Factors
•in California, the Private Attorneys General Act, or PAGA, which empowers employees to bring representative actions for alleged violations of the California Labor Code. As a California-based employer, we face heightened legal and financial exposure under PAGA, including exposure related to scale and complexity of class actions, statutory PAGA penalties, and compliance and defense burden of such claims;
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Furthermore, the C2i Acquisition included acquiring personal data that may originate from, be processed in, or be transferred to and from, Israel, the EU and other jurisdictions. Our ability to process, use and transfer such personal data may
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
Some patients may decide not to use our tests because of price, all or part of which may be payable directly by the patient if the patient’s insurer denies reimbursement in full or in part. There is a growing trend among insurers to shift more of the cost of healthcare to patients in the form of higher co-payments or premiums, putting patients in the position of having to pay more
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
•Prior to its acquisition, C2i was not required to maintain an internal control infrastructure that would meet the standards of a public company, including the requirements of the Sarbanes-Oxley Act of 2002. Beginning in 2024, we began to integrate C2i into our internal control structures and implemented additional internal controls where needed. As we continue to integrate and improve the operations of C2i and other acquired businesses, we may need to implement additional controls. The costs that we may incur to implement such controls and procedures may be substantial and we could encounter unexpected delays and challenges in this implementation. In addition, we may discover significant deficiencies or material weaknesses in the quality of an acquired business’s financial and disclosure controls and procedures;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
•We have experienced quality, regulatory or manufacturing irregularities and challenges in connection with our Marseille, France facility, and we may continue to rely on NanoString as a sole source provider;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
In 2023 and 2024, we experienced significant declines in biopharma and other services revenue as a result of reductions in customer projects, extended sales cycles and overall spending constraints across the industry in the U.S. and internationally. The success and continuity of our biopharma services business depends in part on our ability to identify and successfully negotiate with appropriate pharma partners. We cannot guarantee that our existing partnerships will be successful or that we may identify further appropriate pharma partners and other business relationships. If our existing partners terminate their agreements with us, we may experience disruptions to our business and revenues. Further, depending on the success of our biopharma and other services, including their ability to generate revenues, we may reassess our pursuit of certain non-core businesses from time to time, which may include pausing or discontinuing certain non-core businesses, any of which may have a material adverse effect on our business and financial condition.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
On May 6, 2024, the FDA issued a final rule under 21 CFR Part 809 to make explicit that IVD products are devices under the Federal Food, Drug, and Cosmetic Act, removing much of the FDA's historical enforcement discretion for most LDTs. In conjunction with this final rule, the FDA will phase out its general enforcement discretion approach for LDTs in five stages over a four-year period, and implement targeted enforcement discretion policies for certain categories of IVDs manufactured by a laboratory. Each stage of the proposed phaseout period would subject LDTs to a set of regulatory requirements. For example, the first stage of the phaseout would require LDT developers to comply with medical device reporting requirements, complaint
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
handling and correction and removal reporting requirements within one year after the FDA publishes the final rule. LDTs that are considered higher risk IVDs would be subject to premarket review requirements within three and a half years, and LDTs that are considered moderate or low risk IVDs would be subject to premarket submission requirements beginning four years after the FDA publishes the final rule.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia have each enacted laws similar to the CCPA/CPRA. The multiple layers of privacy law within the United States could increase our potential liability, increase our compliance costs, and adversely affect our business.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Changes to Internal Revenue Code Section 174 under the 2017 Tax Cuts and Jobs Act went into effect in 2022. The revised code no longer permits a deduction for research and development expenditures in the tax year that such costs are incurred. Instead, such costs must be capitalized and amortized over five or 15 years for U.S. and foreign costs, respectively. The new rules will change the utilization of our NOLs and it is uncertain whether the new rules will be repealed or modified in the future.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Our business or financial results may be adversely impacted by uncertain economic conditions, including: regional conflicts globally, turmoil in the global banking and finance system, adverse changes in interest rates, foreign currency exchange rates, tax laws or tax rates; inflation; a recession; the impact of disease outbreak; government shutdown; contraction
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
Some of these items are unique to these suppliers and vendors and their inability to provide us with reagents that perform to specifications, could negatively impact our ability to provide timely response and reports to our customers and, as a result, may materially impact our ability to generate revenue.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many several EU member states have adopted national “Sunshine Acts” which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on medical device manufacturers.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We Our high complexity clinical labs that design, develop and manufacture our laboratory developed tests are subject to CLIA, the Clinical Laboratory Improvement Amendment (CLIA) regulations, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, and the licensor may fail to prevent infringement by third parties, or the licensed patents or other rights could be found to be invalid or unenforceable.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Following the lead of California, several other states, including Colorado, Connecticut, Delaware, Indiana, Iowa, Kentucky, Maryland, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia have each enacted laws similar to the CCPA/CPRA.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Further, we cannot be certain that such agreements have been entered into with all relevant parties, or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The Canada Of the $561.9 million of U.S. federal net operating loss carryforwards carryforwards, $57.5 million will begin to expire in 2034, 2036 while for French purposes, the net operating losses remainder will carryforward indefinitely.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The first Protecting Access to Medicare Act of 2014, or PAMA, data reporting period for CPT 81546 (Afirma GSC), CPT 81542 (Decipher Prostate), and CPT 0016U (Decipher Bladder) under the current triennial data reporting process is expected to occur between May 1 through July 31, 2026 based on the data collection period of January and March 2029. 1 through June 30, 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Under the IVDR, if If any RUO material product is integrated into an IVD, IVD MD, it must be fully validated assessed and documented as part of the device. device and comply with the IVDR.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We cannot predict whether these revisions will delay future This guidance has extended the timelines for development of new LCDs and may result in impeded coverage for our test products, which could have a material negative impact on revenue.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The revised SCCs are not to be relied on for data transfers to non-EEA entities subject to the GDPR, and we are waiting for further guidance on valid mechanisms for data transfers from the EEA to such entities.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
If our general strategy of seeking incremental growth through acquisitions and collaborations is not successful, or if we do not successfully integrate companies or assets that we acquire into our business, our prospects and financial condition will may suffer.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation actions against, healthcare companies based on financial arrangements with health-care providers (including physicians and labs), regulatory compliance, product promotional practices and documentation, and coding and billing practices.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty penalties associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could be required to curtail or cease our operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
We test our intangible assets and other long-lived assets for impairment on an annual basis and we perform regular reviews to determine if any event has occurred that may indicate that the carrying values of our intangible assets with finite lives and other long-lived assets are impaired. If indicators of impairment exist, we assess the recoverability of the affected assets by determining whether their carrying amounts exceed their undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. Factors that may indicate potential impairment include significant changes in the ability of an asset to generate positive cash flows and the pattern of utilization of a particular asset.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On July 16, 2025, the Marseille Commercial Court published a decision approving the divestiture of the contract manufacturing portion of our French subsidiary, Veracyte SAS, to Helio Diagnostics SAS, effective August 1, 2025. The remaining assets of Veracyte SAS will be managed by the judicial administrator until such time that the Marseille Commercial Court appoints a judicial liquidator to solely initiate and manage final liquidation proceedings. Effective August 1, 2025, we ceased to have a controlling interest in Veracyte SAS. As we began judicial restructuring proceedings affecting Veracyte SAS with the Marseille Commercial Court in the second quarter of 2025, we evaluated whether the associated assets of Veracyte SAS were impaired. We concluded, during the second quarter of 2025, that the long-lived assets of the Veracyte SAS asset group were not recoverable. As a result, we recorded a $20.5 million non-cash impairment charge during the year ended December 31, 2025 primarily related to the Company's right-of-use assets; property, plant, and equipment; and certain tax credits.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On July 4, 2025, the One Big Beautiful Bill Act, or the OBBBA, was signed into law. The legislation includes a broad range of tax reform provisions affecting businesses including, but not limited to, the reinstatement of 100% bonus depreciation, immediate expensing of domestic research and development costs, and revisions to the U.S. taxation of profits derived from international operations. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We have assessed the effects of the new tax legislation, including immediate expensing of domestic research and development expenditures, and the results have been reflected in the Form 10-K for the year ended December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
We incur a significant amount of expenses related to activities to secure clinical trial results in support of our testing and product development portfolio and on-market tests, as well as clinical validation and utilization studies. We also deploy state-of-the-art and costly genomic technologies in our discovery experiments, and our spending on these technologies may vary substantially from quarter to quarter. The timing of these research and development activities is difficult to predict, as is the timing of clinical trial enrollments and sample acquisitions. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses can affect our financial results. We conduct clinical studies to validate our new products, as well as on-going clinical studies to further the published evidence to support our commercialized tests. As these studies are initiated, start-up costs for each site can be significant and concentrated in a specific quarter. Spending on research and development, for both experiments and studies, may vary significantly by quarter depending on the timing of these various expenses.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
significant expense as we invest in the continued development of our innovation engine, early-stage products including our MRD tests, required clinical studies and the development of current IVD tests.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
For biopharmaceutical and other revenue, we develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if they can be satisfied at a point in time or over time, and we measure the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amounts to be included in the transaction price. Milestone payments that are not within either party’s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of milestones that are within either party’s control, such as operational developmental milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Revisions to our estimate of the transaction price may also result in negative revenues and earnings in the period of adjustment.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
During the second half of 2024, we strategically entered into longer purchase commitments to stabilize our supply chain, manage inventory risk, and secure optimal pricing for essential supplies. The increase in supplier purchase commitments also reflects the growth in our testing volume. As a result, non-cancelable purchase commitments totaled approximately $43.2 million as of December 31, 2024, compared to approximately $19.4 million at December 31, 2023.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Pursuant to the Agreement and Plan of Merger, dated as of January 5, 2024, by and among the Company, C2i, Canary Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company, Veracyte Diagnostics, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company, and Fortis Advisors LLC, as the C2i securityholders’ agent, or the Merger Agreement, we may be required to pay to certain noteholders of C2i up to an additional $20.0 million in cash or shares of our common stock, at our election, upon the achievement of certain milestones. During the three months ended December 31, 2024, one of the milestones was achieved resulting the payment of $5.0 million. As of December 31, 2024, we expect to achieve a portion or all of the remaining milestones contained in the Merger Agreement within the next 12 months, requiring payments totaling approximately $16.6 million.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
As part of our agreement to acquire the exclusive global diagnostic license to the nCounter Analysis System, we may be required to pay up to an additional $10.0 million in cash, contingent upon first achievement or occurrence, by us or on our behalf, of the commercial launch of the first, second and third diagnostic tests for use on the nCounter multiplex analysis system. As of December 31, 2024, the achievement of one of the milestones is forecasted to occur within the next 12 months, requiring payments totaling $3.5 million.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
Cash used as a result of changes in operating assets and liabilities was $16.4 $2.3 million, primarily comprising an increase in accounts receivable of $4.5 million, a decrease in accrued liabilities of $3.9 million, a decrease in operating lease liability of $3.4 $2.5 million, an increase in prepaid expense and other current assets of $2.1 million, an increase in supplies and inventory of $3.0 $2.9 million, a decrease in accounts payable of $1.0 million, and an increase in other assets accounts receivable of $3.0 $0.7 million, partially offset by an increase in accrued liabilities of $6.3 million and a decrease in prepaid expense and other current assets of $1.4 $0.5 million.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Cash provided by used in financing activities for the year ended December 31, 2023 2025 was $2.8 $4.2 million, consisting of $9.6 $18.3 million in tax payments during the period related to the vesting of restricted stock units granted to employees, partially offset by $14.1 million in proceeds from the exercise of options to purchase our common stock and purchase of stock under our Employee Stock Purchase Plan, or ESPP, partially offset by $6.7 million in tax payments during the period related to the vesting of restricted stock units granted to employees. ESPP.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Cash provided by used in investing activities for the year ended December 31, 2023 2025 was $15.1 $9.2 million consisting of $25.1 $9.7 million used in the acquisition of property and equipment, partially offset by net proceeds of $150.0 million from the purchase and maturity of short-term investments, offset by $10.0 million used in the acquisition of property and equipment. investments.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Biopharmaceutical and other revenue decreased by $5.8 $3.5 million for the year ended December 31, 2024 2025 compared to 2023 driven primarily by 2024, due to the reduction of customer projects decrease in the business conducted in France given overall spending constraints across the industry. restructuring proceedings affecting Veracyte SAS in August 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Other income, net, increased $0.4 $0.8 million for the year ended December 31, 2024 2025 compared to 2023, 2024, primarily due to an increase of $3.8 $6.0 million due to foreign currency revaluation and an increase of $1.6 million of interest and dividend income, partially offset by an increased a loss of $2.8 $6.7 million related due to unrealized foreign currency gain(loss). the deconsolidation of Veracyte SAS.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our cost of biopharmaceutical and other revenue are the consists of costs of performing activities under arrangements that require us to perform license or provide access to our assets or laboratory testing services, as well as costs incurred in providing contracted research and development, contract testing services, commercialization, development and contract manufacturing and development. activities.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
In addition to the these development of new product candidates, activities, we believe these also perform clinical evidence studies which are critical to gaining clinician adoption of new products and our tests, driving favorable coverage decisions by payors payers, as well as gaining guideline inclusion for such products. tests.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
This was primarily due to a $92.4 $74.2 million increase in testing revenue driven by a 23% 19% volume increase and a 4% average selling price increase, $0.7 million increase in our product revenue, partially offset by a $5.8 $3.5 million decrease in our Biopharmaceutical and other revenue, as well as a $1.9 million decrease in our product revenue.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Inventory consists of raw materials consumed in the contract manufacturing process as well as finished and semi-finished components goods used in the assembly of diagnostic kits related to product sales. sales as well as raw materials consumed in the contract manufacturing process.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Other income (loss), net consists primarily of interest income from our cash held in interest bearing accounts, realized and unrealized gains and losses on foreign currency transactions, and and, prior to the restructuring proceedings affecting Veracyte SAS in August 2025, French research tax credits. credits, as well as loss on deconsolidation of Veracyte SAS.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Years Ended December 31, 2025 2024 2023 2022 Net cash provided by operating activities $ 136,307 $ 75,096 $ 44,222 $ 7,535 Net cash (used in) provided by investing activities (9,209) (56,275) 15,112 Net cash (used in) investing activities (56,275) 15,112 (29,387) Net cash provided by financing activities (4,222) 4,904 2,837 3,494
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer, either on its own or together with other resources that are readily available to the customer, and is separately
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.